부산대학교 도서관

Study Objective: To assess the association between tenofovir diphosphate (TFV‐DP) in dried blood spots (DBS), a measure of cumulative tenofovir‐based antiretroviral (ART) adherence, with medication regimen complexity in persons with human immunodeficiency virus (PWH). Design: Prospective clinical cohort (up to three visits over 48 weeks). Setting: Academic‐based HIV clinic. Patients: PWH receiving tenofovir disoproxil fumarate (TDF)‐based ART. Measurements: DBS for TFV‐DP were collected at every study visit. Baseline patient‐level medication regimen complexity index (pMRCI) scores were calculated and categorized into three sub‐scores (disease‐specific [ART], non‐ART, and over‐the‐counter [OTC]). The pMRCI scores were evaluated to assess the association with TFV‐DP in DBS <350 fmol/punch after adjusting for clinical covariates. pMRCI scores were also categorized to estimate the adjusted relative risk (aRR) of having a TFV‐DP <350 fmol/punch between pMRCI quartiles. Main Results: Data from 525 participants (1,146 person‐visits) were analyzed. Baseline median (interquartile range [IQR]) pMRCI scores for participants with TFV‐DP in DBS <350 vs. ≥350 fmol/punch were 4 (3, 8) vs. 4 (2, 6) for ART, 27 (12, 31) vs. 12 (5, 22) for non‐ART, and 0 (0, 1) vs. 0 (0, 2) for OTC, respectively. For the non‐ART scores, the aRR for having a TFV‐DP in DBS <350 fmol/punch was 6.4 (95% CI: 2.0, 20.6; P=0.002) when comparing participants in the highest pMRCI quartile with those in the lowest quartile. Conclusions: Higher pMRCI for non‐ART medications is associated with lower adherence as measured by TFV‐DP in DBS. Future research should investigate whether reducing non‐ART medication complexity improves ART adherence and exposure in PWH. [ABSTRACT FROM AUTHOR]